As feed consumption continues to grow, many or our publishers are adding more and more feeds to their Google accounts, and wishing to analyze, publicize, and monetize those feeds through the combination of AdSense for feeds and FeedBurner. Because of this trend, one of the most frequent questions we receive is “How do I export stats for all my feeds at once?”
As of today, you can now export your subscriber, reach, hits, item click-throughs, podcast downloads, and item views directly from the FeedBurner application on the My Feeds page. You are then at your leisure to slice, dice, add, subtract, and even multiply and divide your stats however you may wish.
As always, aggregate revenue, impressions, and clicks, and eCPM can be downloaded from your AdSense account or Google Ad Manager account (if you have been enabled to sell your own direct ads in feeds through Google Ad Manager) on the Reports tabs.
Also, as a reminder - if you wish to export feed subscriber statistics in timeframes other than those provided, you can do that through the FeedBurner
Awareness API.
Posted by Steve Olechowski, Google Product Managment
Continue Reading April 16th, 2009
Over the last week, and as reported in the FeedBurner status blog , we experienced a technical issue that caused us to report reduced subscribers from Google Feedfetcher in your feed analytics at FeedBurner and AdSense.
Our engineers have resolved the issue, and been able to rebuild stats from our logs such that the totals should now be correct. Please note that in the past, we were not able to correct historical statistical anomalies, but are now able to do so, always using the actual traffic data.
No data was lost during this process, nor were any subscribers actually unsubscribed from your feed. All feed content was delivered to all subscribers who wished to view the content, regardless of the numbers reported. Ad impression reporting and revenue were unaffected by these subscriber reporting issues.
We apologize for the inconvenience and appreciate your patience as we continue to merge our systems with other Google systems behind the scenes.
Posted by Steve Olechowski, Google Product Management
Continue Reading April 13th, 2009
MUMBAI | BANGALORE: Fortis Healthcare has emerged as the front-runner to acquire a substantial stake in the unlisted Wockhardt Hospitals, people familiar with the development said.
Fortis’ promoters have reached a broad agreement with Wockhardt’s founder Habil Khorakiwala on a possible deal to acquire up to 74% in the hospital chain for close to Rs 750 crore, valuing the business at over Rs 1,000 crore, the people said. Wockhardt Hospitals is a 100% subsidiary of pharmaceutical company Wockhardt.
Private equity firms General Atlantic and Advent were also in the race, but Fortis is close to clinching the deal, they added.
Investment bankers said if the deal materialises, Fortis, which is run by Shivinder Singh the younger brother of Ranbaxy’s MD and CEO Malvinder Singh is likely to invest Rs 400 crore in the first phase for a 40% equity holding, and plans to subsequently increase its stake. But a formal deal is yet to be sealed, with both parties in the process of ironing out differences, including those over branding the hospital chain.
When contacted, a Wockhardt spokesperson refused comment. A Fortis Healthcare spokesperson said: “We are in the market. We cannot comment on market speculation or any individual deals.”
Bankers told ET that Fortis’ promoters and Mr Khorakiwala had reached an agreement almost 10 days ago. One banker said Fortis is valuing the hospital chain at over Rs 1,000 crore, which is substantially lower than the proposed IPO valuation, arrived at almost 15 months ago. In February 2008, Wockhardt had sought to divest 24% for Rs 800 crore. The issue had to be withdrawn because of lack of demand.
Since the time Fortis entered the fray, investment banking circles have been wary of ‘control’ issues. The group has, in the past, walked out of deals with other hospitals over differences on management rights.
“A staggered deal could be a way out,” said an analyst, who argued that selling some pharma assets and a strategic dilution in the hospital business was critical to Wockhardt’s fiscal restructuring plans. On Monday, the Fortis scrip ended marginally lower at Rs 66 on the BSE in a weak market.
Fortis currently manages 3,000 beds with a network of 26 hospitals, which it plans to increase to 40 by 2012. It will add 1,200 beds soon at new facilities in Vashi in Navi Mumbai, Shalimar Bagh in Delhi and Gurgaon.
Industry analysts feel rising incomes and a demand for quality healthcare with an efficient government-run health delivery system not in place are fuelling the growth of hospital chains in India. The sector grows at an estimated 10% to 15 % a year.
Wockhardt Hospitals, which runs 17 facilities, is planning more at Kolkata, Mumbai and Nashik, which will start functioning within a month. If the deal materialises, Fortis will obtain easy entry into Maharashtra, Bangalore and Kolkata. The deal will take its network strength to 43.
Fortis Healthcare is in the process of raising Rs 1,000 crore through a rights issue. The company had said the money would be used to fund its greenfield projects and restructure the balance sheet, besides being utilised for other investments.
Additionally, the company plans to raise money through issue of warrants, but the details are yet to be decided.
In January this year, it had bought a controlling stake in Mauritius-based hospital, Clinique Darne, in a joint venture with Mauritian industrial group CIEL that operates in agro-industry, textiles and equity investment.
Continue Reading April 1st, 2009
AHMEDABAD: Zydus Cadila, the Ahmedabad- based Rs 2300 crore pharma major, eyes large chunk of revenue generation from its new drug discovery pact with global drug giant Eli Lilly. Zydus believes that it would receive potential milestone payment of up to $300 million and also royalties on sales upon the successful launch of any compounds derived from the research programme.
In a company release, Zydus informs that it has signed a new drug discovery and development agreement with Eli Lilly for cardiovascular research. The collaborative research programme may continue for a span of up to six years.
Zydus will work to discover and develop potential molecules against a novel target, primarily in the area of cardiovascular research. Zydus will initiate the drug discovery, lead identification and optimization, and conduct preclinical studies and clinical trials up to Phase II Human Proof-of-Concept.
While Eli Lilly will provide chemical starting points as well as expertise and feedback regarding toxicology, ADME, chemistry, biology, clinical and regulatory aspects as needed to potentially increase the probability of success of the programme. As part of the agreement, Lilly will have an option to license any resulting molecules at different stages.
Describing the research agreement as a new paradigm for global alliances in drug discovery and development, chairman and managing director of Zydus Cadila, Mr. Pankaj R. Patel said, We are delighted to embark on this programme with Lilly and create a new benchmark in collaborative research programmes.
The Zydus Research Centre (ZRC), the dedicated research arm of the group, has a team of over 350 research professionals, spearheading the quest of creating healthier and happier communities globally. The centre is engaged in new drug discovery, novel biologics and NDDS research.
The group has a strong research pipeline of 6 NMEs in various stages of clinical trials of which, five NMEs are targeted at cardiometabolic disorders.
Continue Reading April 1st, 2009
MUMBAI: A unit of India’s Cadila Healthcare Ltd has signed a drug development deal with Eli Lilly and Co that could earn it up to $300 million in milestone payments plus royalties, driving its shares up nearly 16 percent on Monday.
Zydus Cadila said it would earn royalties from any drugs for cardiovascular diseases developed by the partnership, which could run for up to six years.
Zydus Cadila will be responsible for identifying potential drug candidates and developing them through to mid-stage clinical trials. Lilly will provide the potential molecules and expertise and feedback for clinical, regulatory and research work.
Global drug giants, faced with thinning new drugs pipeline and stiff competition from generic drugs, are increasingly outsourcing drug development work to firms in countries such as India to help cut costs and shorten the time for a drug launch.
Lilly has struck partnerships with other Indian firms, including Piramal Life Sciences, Suven Life Sciences and Jubilant Organosys.
Cadila shares rose as much as 15.6 percent of 297 rupees on the news, its highest in almost six months. At 12:51 pm 0721 GMT, its shares were up 6.3 percent at 273 rupees in a Mumbai market down 4.2 percent.
Continue Reading April 1st, 2009
Previous Posts
